Iodotubercidin

Iodotubercidin

SCHEMBL29375718

Nc1ncnc2c1c(I)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 16/20 0.83
SLC29A1 Q99808 1/20 0.75
DOT1L Q8TEK3 3/20 0.71
NPC1 O15118 1/20 0.71
GALR3 O60755 1/20 0.71
S1PR4 O95977 1/20 0.71
ALDH1A1 P00352 1/20 0.71
MAPT P10636 1/20 0.71
S1PR1 P21453 1/20 0.71
HTT P42858 1/20 0.71
RAB9A P51151 1/20 0.71
PAX8 Q06710 1/20 0.71
HASPIN Q8TF76 1/20 0.67
DCLK1 O15075 1/20 0.65
DAPK3 O43293 1/20 0.65
DYRK3 O43781 1/20 0.65
CDK1 P06493 1/20 0.65
ROS1 P08922 1/20 0.65
RPS6KB1 P23443 1/20 0.65
CDK2 P24941 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodotubercidin SCHEMBL12618424 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL2786488 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL12505209 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL29383008 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL319225 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL13021361 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL12652819 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL8328935 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL16978206 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3
Iodotubercidin SCHEMBL2043545 1.00 ADK (0.83) ADKSLC29A1DOT1LNPC1GALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602148-A1 METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS Peking University (CN) 2025-08-20 EP claimed
WO-2024078119-A1 METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS PEKING UNIVERSITY (CN) 2024-04-18 WO claimed
WO-2023059810-A1 STENTS AND METHODS OF USE UNIVERSITY OF CONNECTICUT (US) 2023-04-13 WO claimed
WO-2023044463-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS UNIVERSITY OF CONNECTICUT (US) 2023-03-23 WO claimed
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 WO claimed
CN-122055439-A Methods for differentiating dopaminergic neurons from stem cells 艾斯本神经科学公司 2026-05-15 CN disclosed
EP-3129065-B1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS AKAMARA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS TUFTS COLLEGE (US) 2026-05-07 US disclosed
EP-4734896-A2 BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-4735018-A2 CENTRIFUGALLY-MOLDED ARTICLES AND METHODS Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-4728055-A2 METHODS FOR DIFFERENTIATING DOPAMINERGIC NEURONS FROM STEM CELLS Aspen Neuroscience, Inc. (US) 2026-04-22 EP disclosed
US-12590294-B2 Process for producing cardiomyocytes OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2026-03-31 US disclosed
US-20220175738-A1 Tip60 Inhibitors and Methods of Use for Cardiovascular Disease THE MEDICAL COLLEGE OF WISCONSIN, INC. 2022-06-09 US disclosed
WO-2022098880-A1 TOPICAL FORMULATION COMPRISING OMEGA-3 FATTY ACIDS, MELATONIN AND VITAMIN D AMBO INNOVATIONS LLC (US) 2022-05-12 WO disclosed
WO-2022098992-A1 USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2022-05-12 WO disclosed
US-11318230-B2 Platelet-derived growth factor compositions and methods of use thereof BIOMIMETIC THERAPEUTICS, LLC (US) 2022-05-03 US disclosed
US-20220072204-A1 Platelet-Derived Growth Factor Compositions and Methods of Use Thereof BIOMIMETIC THERAPEUTICS LLC (US) 2022-03-10 US disclosed
WO-2022040566-A1 METHODS AND USES OF HALOFUGINONE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-24 WO disclosed
US-11247181-B2 Biomimetic multilayer compositions TRUSTEES OF TUFTS COLLEGE (US) 2022-02-15 US disclosed
EP-3947463-A1 TREATMENT OF CANCER UTILIZING AN IDENTIFIED ADENOSINE FINGERPRINT Arcus Biosciences, Inc. (US) 2022-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS PTMS, ITK, MATK ADK 931/4885SLC29A1 4565/4885DOT1L 1384/4885
US-12590294-B2 Process for producing cardiomyocytes RARB, RARA, FABP3 ADK 1802/4885SLC29A1 3917/4885DOT1L 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.